Deltex Medical

www.deltexmedical.com TICKER: DEMG     EXCHANGE: L

Deltex is a UK medical technology company, marketing a proprietary, minimally invasive real-time haemodynamic monitoring system (CardioQ-ODM) which uses Doppler (ultrasound) technology. It is utilised in operating theatres, intensive care units (ICUs) and Accident & Emergency (A&E) departments and provide individualised Doppler Guided Fluid Management allowing for the early assessment and early intervention on the patient's haemodynamic status. CardioQ-ODM measures the blood flow velocity in the descending aorta, through the insertion of a flexible disposable probe in the patient's oesophagus via either the mouth or the nose. CardioQ-ODM is part of an Enhanced Recovery multi-disciplinary programme embracing the three key stages of surgery: prepreoperative, perioperative for the overall improvement of the quality of care by getting better sooner and reduce the length of stay and benefiting the healthcare budgets.

LATEST REPORTS

 
Flowing in the right direction
Published: Jul 31 2017

Deltex Medical (DEMG) is a UK based manufacturer of minimally invasive haemodynamic monitoring technology: ODM is the only technology to measure continuously blood flow in the central circulation in real time, enabling clinicians to respond quickly to changes in flow and to optimise patient care. The recent H1’17 trading statement supports our view that DEMG has reached a turning point after a challenging period in UK. Total sales increased 7% to £2.9m. Analysing regional sales of single use probes associated with the CardioQ-ODM monitoring system: US revenues grew 35% from £

REGISTER / LOGIN TO VIEW THIS RESEARCH IN FULL

 
An improving picture, a sharper focus
Published: May 04 2017

Deltex Medical is a UK based manufacturer of minimally invasive haemodynamic monitor technologies: ODM is the only technology to measure continuously blood flow in the central circulation in real time, enabling clinicians to respond quickly to changes in flow and to optimise patient care. The key revenue stream is from global sales of consumables notably probes, with key markets being US and UK.FY16 group revenues of £6.3m, marginally lower than the £6.4m total in FY15 however, with sustained momentum from US probe sales, up 40% to £1.9m in FY16, offsetting UK weakness. Gross

REGISTER / LOGIN TO VIEW THIS RESEARCH IN FULL

 
Resetting the trend, probe sales positive
Published: Jan 18 2017

FY16 group revenues reached £6.3m in FY16 vs £6.2m (ex-research barter sales of £0.2m) marginally lower than the £6.4m total in FY15. KPI probe sales reached £5.4m (£5.2m) with sustained momentum from US revenues, up 40% to £1.9m in FY16, counterbalancing UK weakness. Looking ahead, with two new platform accounts added post year end, DEMG has reached a milestone of 30 US platform accounts, which could see higher margin US sales outperform other geographies for the first time in 2017. By contrast, as flagged, UK sales declined 26% vs FY15 to £

REGISTER / LOGIN TO VIEW THIS RESEARCH IN FULL

 
View the Results Webinar
Published: Sep 16 2016

You can now hear Ewan Phillips, CEO, present the interim results for the six months ended 30 June 2016 for Deltex Medical and answer investor questions.To view simply click on the video below.

REGISTER / LOGIN TO VIEW THIS RESEARCH IN FULL

 
American beauty : strategy on track
Published: Sep 08 2016

Deltex Medical manufactures and markets haemodynamic monitoring technologies: ODM is the only technology to measure continuously blood flow in the central circulation in real time. Randomised, controlled trials using Doppler have demonstrated that early fluid management intervention will reduce post-operative complications, reduce intensive care admissions, and reduce the length of hospital stay.Interim results showed strong progress in the key US market. For the first time probe sales in the US, at £848k, exceeded those in the UK. That represents 39% growth in the region compared to H1

REGISTER / LOGIN TO VIEW THIS RESEARCH IN FULL

 
Strategy USA: it's showtime!
Published: Jul 25 2016

Deltex markets minimally invasive and real time Doppler (ultrasound) cardiac function monitoring systems used for both surgery and critical care in hospitals worldwide.FY2015 results highlighted satisfactory progress through a year affected by divergent market trends. The UK haemodynamic monitoring market declined again, with little turnaround prospects in sight; significantly, the US and International markets demonstrated good growth and a strong future potential.  Most encouragingly, US revenues increased 41% to £1.5m in FY2015. The growth trajectory continued to improve, with pro

REGISTER / LOGIN TO VIEW THIS RESEARCH IN FULL

 
USA offers enhanced prospects
Published: Mar 20 2015

REGISTER / LOGIN TO VIEW THIS RESEARCH IN FULL

ARCHIVE

2015
USA opportunity is the main mission
Published: Jan 20 2015

REGISTER / LOGIN TO VIEW THIS RESEARCH IN FULL

2014
Go West! USA promising, but UK tough
Published: Oct 05 2014

REGISTER / LOGIN TO VIEW THIS RESEARCH IN FULL

All set for the Premier League
Published: Mar 19 2014

REGISTER / LOGIN TO VIEW THIS RESEARCH IN FULL

Strong Year for surgical probe growth - particularly in the UK
Published: Jan 08 2014

REGISTER / LOGIN TO VIEW THIS RESEARCH IN FULL

2013
Improving Probe Prospects
Published: Sep 26 2013

REGISTER / LOGIN TO VIEW THIS RESEARCH IN FULL

Maintaining key product flow
Published: Jul 15 2013

REGISTER / LOGIN TO VIEW THIS RESEARCH IN FULL

Over here, and over there
Published: Apr 23 2013

REGISTER / LOGIN TO VIEW THIS RESEARCH IN FULL

Building blocks for growth
Published: Jan 08 2013

REGISTER / LOGIN TO VIEW THIS RESEARCH IN FULL

2012
Steady progress at half-year
Published: Sep 26 2012

REGISTER / LOGIN TO VIEW THIS RESEARCH IN FULL

Past, present and future
Published: Mar 21 2012

REGISTER / LOGIN TO VIEW THIS RESEARCH IN FULL

2011
More key endorsements
Published: Dec 07 2011

REGISTER / LOGIN TO VIEW THIS RESEARCH IN FULL

Still on track
Published: Sep 22 2011

REGISTER / LOGIN TO VIEW THIS RESEARCH IN FULL

Balancing act in H1 2011
Published: Jul 20 2011

REGISTER / LOGIN TO VIEW THIS RESEARCH IN FULL

NICE to see you...
Published: Apr 04 2011

REGISTER / LOGIN TO VIEW THIS RESEARCH IN FULL

Back to double-digit growth
Published: Mar 08 2011

REGISTER / LOGIN TO VIEW THIS RESEARCH IN FULL

Moving ahead with confidence
Published: Jan 13 2011

REGISTER / LOGIN TO VIEW THIS RESEARCH IN FULL

2010
Proof of the pudding
Published: Nov 08 2010

REGISTER / LOGIN TO VIEW THIS RESEARCH IN FULL

A good diagnosis
Published: Sep 23 2010

REGISTER / LOGIN TO VIEW THIS RESEARCH IN FULL

Beating the headwinds
Published: Mar 26 2010

REGISTER / LOGIN TO VIEW THIS RESEARCH IN FULL

NHS breakthrough
Published: Jan 15 2010

REGISTER / LOGIN TO VIEW THIS RESEARCH IN FULL

2009
Interims
Published: Sep 11 2009

REGISTER / LOGIN TO VIEW THIS RESEARCH IN FULL

Progress in 2008
Published: Mar 11 2009

REGISTER / LOGIN TO VIEW THIS RESEARCH IN FULL

2008
Progress in line with expectations
Published: Sep 23 2008

REGISTER / LOGIN TO VIEW THIS RESEARCH IN FULL

Continuing to hit key milestones
Published: Apr 14 2008

REGISTER / LOGIN TO VIEW THIS RESEARCH IN FULL

Still moving forward
Published: Jan 23 2008

REGISTER / LOGIN TO VIEW THIS RESEARCH IN FULL

2007
US reimbursement granted
Published: Jul 23 2007

REGISTER / LOGIN TO VIEW THIS RESEARCH IN FULL

Deltex; Oesophageal Doppler Monitoring recommended for reimbursement coverage in US
Published: Feb 28 2007

REGISTER / LOGIN TO VIEW THIS RESEARCH IN FULL

Deltex Medical; positive pre-close trading update
Published: Jan 16 2007

REGISTER / LOGIN TO VIEW THIS RESEARCH IN FULL

2006
Deltex Medical; steady progress
Published: Oct 25 2006

REGISTER / LOGIN TO VIEW THIS RESEARCH IN FULL

Deltex Medical; innovative technology positioned to target huge market
Published: Apr 26 2006

REGISTER / LOGIN TO VIEW THIS RESEARCH IN FULL